title: Single-dose daclizumab induction therapy in patients with liver transplantation.
abstract: OBJECTIVE
  To investigate the efficacy and safety of a single-dose daclizumab induction therapy in orthotopic liver transplantation (OLTx).
  
  
  METHODS
  A retrospective study was made for 54 cases of OLTx in recent three years. The daclizumab group consisted of 23 cases of OLTx who received single-dose of 2 mg/kg intravenously after postoperative 24 hours. The control group consisted of the remaining 31 patients. Additional immunosuppressors included steroids, mycomphenolate mofetil, facrolimus or microemulsion cyclosporine used in all patients. Meta-statistical analysis was made for general data, incidence of acute rejection and infection, postoperative clinical course, complications and prognosis between two groups.
  
  
  RESULTS
  Pretransplant demographies were not significantly different between two groups. In the induction group there were significantly less acute rejection episodes (5 of 23, 21.74 %) than those in the control group (12 of 31, 38.71 %), which were proved by pathologic diagnosis (P<0.05). The incidence of infection at the early stage was not significantly different between two groups.
  
  
  CONCLUSIONS
  Induction therapy with single-dose of daclizumab is safe and effective and appears to be able to reduce the incidence of acute rejection.
authors.affiliation: Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China. yanlunan@hotmail.com
authors.forename: Lu-Nan
authors.initials: LN
authors.lastname: Yan
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.forename: Bo
authors.initials: B
authors.lastname: Li
authors.forename: Shi-Chun
authors.initials: SC
authors.lastname: Lu
authors.forename: Tian-Fu
authors.initials: TF
authors.lastname: Wen
authors.forename: Qi-Yuan
authors.initials: QY
authors.lastname: Lin
authors.forename: Yong
authors.initials: Y
authors.lastname: Zeng
authors.forename: Nan-Sheng
authors.initials: NS
authors.lastname: Cheng
authors.forename: Ji-Chun
authors.initials: JC
authors.lastname: Zhao
authors.forename: Yue-Meng
authors.initials: YM
authors.lastname: Dai
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000077561:Daclizumab; D004334:Drug Administration Schedule; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage*; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007275:Injections, Intravenous; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011182:Postoperative Care; D012189:Retrospective Studies
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000077561:Daclizumab